Immunovant
New York, US · 1 known investors
Immunovant is a clinical-stage biopharmaceutical company developing treatments for people with autoimmune diseases, with a focus on therapies targeting the FcRn receptor. It advances a pipeline of candidates across multiple therapeutic areas through clinical trials.
BiotechHealthtech
Founders & leadership
CV
Christopher Van TuylExecutive
MG
Michael GeffnerExecutive
PS
Pete SalzmannExecutive
JS
Jay StoutExecutive
MG
Melanie GloriaExecutive
ER
Eva Renee BarnettExecutive
BM
Bill MaciasExecutive
Board
EV
Eric VenkerBoard director
FT
Frank TortiBoard director
AF
Andrew FromkinBoard director
AP
Atul PandeBoard director
GM
George MigauskyBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$450M disclosed across 1 round · 2025
▶$450MraisedJan 2025 · 11 investors · PharmaceuticalsRule 506(b)
▶$450MraisedJan 2025 · 11 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Christopher Van TuylExecutive Officer
- Michael GeffnerExecutive Officer
- Andrew FromkinDirector
- Atul PandeDirector
- George MigauskyDirector
- Eric VenkerDirector
- Frank TortiDirector
- Pete SalzmannExecutive Officer, Director
- Jay StoutExecutive Officer
- Melanie GloriaExecutive Officer
- Eva Renee BarnettExecutive Officer
- Bill MaciasExecutive Officer
- Douglas HughesDirector
- Offering amount
- $450M
- Amount sold
- $450M
- First sale
- Jan 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapSignant Health34 shared keywordsSignant Health provides eClinical technology and services for clinical trial data collection, including electronic data capture, patient and site data solutions, and scientific and operational support. It serves pharmaceutical sponsors and CROs running global clinical trials to generate high-quality data for trial decisions and regulatory submissions.
Guardant Health32 shared keywordsGuardant Health develops blood-based testing (liquid biopsy) for cancer detection and monitoring across all stages of the disease. The company serves oncologists, patients, and biopharmaceutical firms with FDA-approved tests for cancer screening, early-stage risk assessment, and treatment selection.
Companies competing with Immunovant for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Immunovant do?
- Immunovant is a clinical-stage biopharmaceutical company developing treatments for people with autoimmune diseases, with a focus on therapies targeting the FcRn receptor. It advances a pipeline of candidates across multiple therapeutic areas through clinical trials.
- Who are Immunovant's investors?
- Immunovant's investors include Altium Capital.
- How much funding has Immunovant raised?
- Immunovant has disclosed $450M raised across 1 round.
- Where is Immunovant headquartered?
- Immunovant is headquartered in New York, US.